Prometheus Biosciences Inc
NASDAQ:RXDX
Prometheus Biosciences Inc
NASDAQ:RXDX
Price:
199.92 USD
0.09%
Updated:
May 17, 2024
P/S
Price to Sales
Price to Sales
2 387.7
Current
754.5
Median
8.2
Industry
Higher
than median
Higher
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=2 387.7
Market Cap
/
9.5B
Revenue
4m
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| US |
|
Prometheus Biosciences Inc
NASDAQ:RXDX
|
9.5B USD | 2 387.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
290.2B USD | 5.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.8B USD | 5.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.6B USD | 11.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.7B USD | 8.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.3B AUD | 6.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.6B USD | 3.1 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
50.8B USD | 9.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.5B USD | 3.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.4T KRW | 18.1 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
4 555.4
2-Years Forward
P/S
5 073.9
3-Years Forward
P/S
105.6
You don't have any saved screeners yet
